Skip to main
HSCS

HSCS Stock Forecast & Price Target

HSCS Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

HeartSciences Inc. is demonstrating significant financial improvement, with upward revisions to its FY26 earnings per share (EPS) estimates reflecting reduced expenses and a growing share count, indicating effective cost management and business scaling. The company's revised price target of $9.20 highlights the potential for substantial growth as it capitalizes on the increasing adoption of its AI-powered ECG diagnostic solutions across various healthcare settings. Furthermore, the expansion of its average shares outstanding from 0.9 million to 3.2 million suggests robust engagement in equity financing, aligning with the company's ambitions to capture a substantial market share in cardiac diagnostics.

Bears say

HeartSciences Inc. faces a challenging financial outlook, as evidenced by a significant reduction in revenue estimates for FY2026-2027, dropping to $0.0 million and $0.4 million, respectively. Operating expenses remain substantial at $2.1 million, indicating a potential cash burn without a clear path to profitability amidst ongoing uncertainties. Additionally, numerous risks, including liquidity concerns, regulatory hurdles, and competitive pressures, further compound the negative outlook on the company's ability to successfully commercialize its AI-ECG diagnostic solutions.

HSCS has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Heart Test Laboratories Inc (HSCS) Forecast

Analysts have given HSCS a Strong Buy based on their latest research and market trends.

According to 1 analysts, HSCS has a Strong Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Heart Test Laboratories Inc (HSCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.